Ribavirin Litigation Set To Rest: Valeant's Appeal In Patent Case Dismissed
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant requested the dismissal. The company's appeal was largely premised on FDA approval of a citizen petition concerning ribavirin generics' ability to "carve out" protected labeling; the agency denied the petition in April.